Search the Newsreel

How Investors Are Reacting To Concentra Group Holdings Parent (CON) Earnings Beat, Guidance Hike And CEO Transition

Concentra Group Holdings Parent, Inc. (CON) reported strong second-quarter 2026 results, beating earnings expectations and raising its full-year guidance for both revenue and net income. The company also announced a planned CEO transition and continues its share repurchase program and dividend distribution. These developments …

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Citius Oncology, Inc. (NASDAQ:CTOR) is anticipated to reach profitability by 2027, according to analysts, after posting a significant loss in its most recent financial year. The company is projected to achieve a profit of US$12 million in 2027, driven by an estimated annual growth …

Oncoclinicas (ONCO3) vê prejuízo saltar 234%, para R$ 475 milhões; empresa tem ajustes contábeis 'significativos'

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $4.60, significantly higher than its recent share price of $1.96. The company recently exceeded earnings estimates for the quarter, reporting a loss of …

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts

Analysts have given Pyxis Oncology (NASDAQ:PYXS) a "Moderate Buy" rating, with eight out of ten recommending a buy, one a hold, and one a sell, and an average 12-month price target of $7.50. Recent analyst actions have been mixed, including a downgrade from Wall …

How Investors Are Reacting To Concentrix (CNXC) Surging AI Bookings And Shift Toward Debt Reduction

Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Citius Oncology (NASDAQ:CTOR) reported its quarterly earnings, missing analyst expectations with an EPS loss of $0.08 against an estimated $0.07, and revenue of $1.49 million, below the $2.50 million estimate. Despite the misses, the stock price rose 10% to $0.91 on Friday with double …

Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?

Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the August 10 agreement, the companies will combine select clinical-stage assets from BeOne with Revolution's four clinical-stage RAS(ON) inhibitors to evaluate …

Brand Concepts Q1 FY27 EBITDA jumps 50% YoY; net loss widens

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares

CG Oncology (CGON) sees Foresite Capital report 4.9% beneficial stake via funds

Foresite Capital funds and James B. Tananbaum have reported beneficial ownership in CG Oncology (CGON) via a SCHEDULE 13G/A filing. While individual funds hold stakes under 5%, James B. Tananbaum, managing member of the involved Foresite Capital entities, is deemed to beneficially own 4,306,174 …

Concentra Group Holdings Parent Inc stock hits all-time high at 35.16 USD

Concentra Group Holdings Parent Inc. stock has reached an all-time high of $35.16, contributing to a market capitalization of $4.48 billion and marking a 79% year-to-date return. Despite its overvalued status according to InvestingPro, the company demonstrates strong financial health with a Piotroski Score …

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss

Kura Oncology (KURA) investors report up to 9.7% beneficial ownership stakes

Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen have reported significant beneficial ownership stakes in Kura Oncology, Inc. Montanova Capital and Aaron Cowen each own 9.7% of the common stock, while Averill Master Fund holds 8.8%. The reported shares are directly owned …

Citius Oncology's LYMPHIR has 44 ordering institutions, 383 July vials

Cardiff Oncology (CRDF) asks investors to double authorized common shares

Cardiff Oncology (CRDF) is seeking stockholder approval to significantly increase its authorized capital stock, specifically doubling its common stock from 150 million to 300 million shares. This move aims to provide the company with greater flexibility for future financings, strategic transactions, equity incentives, and …

TCG Crossover group (NASDAQ: ALXO) reports 4.2% ALX Oncology stake in 13G/A

TCG Crossover investment entities and Chen Yu have updated their reported ownership in ALX Oncology Holdings Inc. through an amended Schedule 13G filing. Chen Yu is deemed to beneficially own 4.2% of ALX Oncology's common stock, totaling 5,655,487 shares, through TCG Crossover Fund II, …

Pyxis Oncology (PYXS) CEO receives 250,956-share performance-based option grant

Pyxis Oncology's Interim CEO, Thomas Civik, has been granted a performance-based stock option for 250,956 shares, which vested on August 12, 2026. The option has an exercise price of $1.49 per share and an expiration date of February 3, 2036. This vesting occurred after …

Cullinan Therapeutics, Inc. - Common Stock (CGEM) Stock Price, News, Quote & History

This article provides comprehensive information on Cullinan Therapeutics, Inc. (CGEM), including its current stock price, financial metrics, and a history of recent news and press releases. The company, a biopharmaceutical firm, focuses on developing cancer therapies and has announced several key clinical milestones and …

Kura Oncology (NASDAQ:KURA) Stock Price Up 8% on Analyst Upgrade

Kura Oncology (NASDAQ:KURA) saw its stock price rise 8% following an analyst upgrade from Wedbush, which increased its price target to $38 from $36 while maintaining an "outperform" rating. The company's Q2 results surpassed expectations with a narrower loss and higher revenue, driven by …

A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40

This article provides a quick overview of analyst ratings for Kura Oncology (KURA.US), noting a forecast price range of $23 to $40. It indicates that the company is currently receiving a 'Buy' rating from analysts, reflecting positive sentiment. The information is presented as a …

Concentrix Corp (CNXC): Kopernik funds disclose 5.3% beneficial stake

Kopernik Global Investors, LLC and David B. Iben have reported a beneficial ownership of 5.3% in Concentrix Corp (CNXC) common shares, totaling 3,241,584 shares. This stake is held on behalf of their investment advisory clients, with no single client owning more than 5%. The …

JPMorgan Chase & Co. Has Lowered Expectations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price

Concentra Group Holdings Parent (NYSE:CON) Sets New 1-Year High - Here's Why

Concentra Group Holdings Parent (NYSE:CON) has reached a new 52-week high of $35.33, driven by positive analyst sentiment and strong financial performance. The company surpassed quarterly earnings expectations with an EPS of $0.52 and revenue of $606.03 million, marking a 10% year-over-year increase. Despite …

Armistice Capital (TMCI) discloses 6.36M-share Treace Medical ownership stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership stake of 6,364,000 shares in Treace Medical Concepts, Inc. (TMCI), representing 9.79% of the outstanding common stock. This ownership is held directly by Armistice Capital Master Fund Ltd., with Armistice Capital serving as …

Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9,353,553 shares of Citius Oncology, Inc. common stock, which represents a 9.99% stake in the company. They hold shared voting and dispositive power over these shares, which are directly held by Armistice …

Kura Oncology FY2029 EPS Cut by Brookline Capital Markets

CG Oncology (CGON): RTW Investments takes 9.7% position, holding 8.5M shares

RTW Investments, LP and Roderick Wong, M.D. have reported a 9.7% beneficial ownership in CG Oncology, Inc. (CGON), totaling 8,514,590 common shares. These shares are held by RTW-managed funds, with RTW Investments and Dr. Wong sharing voting and dispositive power. The ownership percentage is …

Concentrix Conference: AI Bookings Surge 400% as Offshoring Pressures Sales

Key Points Interested in Concentrix Corporation? Here are five stocks we like better. AI bookings surged 400% year over year in Concentrix's second quarter, with Intelligent Experience revenue expected to reach about $120 million in annual recurring revenue by year-end. Management said deployments can …

China Conch Venture Sets Board Meeting to Approve Interim Results and Consider Dividend

ImmuneOnco Sets August Board Meeting to Approve Interim Results and Mull Dividend

Top Once Upon A Farm (OFRM) Competitors 2026

BofA Securities Adjusts Concentra Group Price Target to $40 From $36

BofA Securities has increased its price target for Concentra Group to $40 from the previous $36. The firm maintains a Neutral rating on the company's stock. This adjustment reflects a revised outlook on Concentra Group by BofA Securities.